Unlike many other cancers, most pancreatic tumors are rock hard.
“That’s one reason why pancreatic cancer is one of the most lethal types of cancer,” says Kenneth Olive, PhD, associate professor of medicine and pathology & cell biology at Columbia University Vagelos College of Physicians and Surgeons and a pancreatic cancer researcher at the Herbert Irving Comprehensive Cancer Center.
“Pancreatic tumors recruit a thick layer of connective tissue called stroma that hardens the tumor and acts like a shield,” says Olive, whose previous research first uncovered how the stroma makes it difficult for chemotherapy drugs to reach malignant cells. “As a result, most chemotherapy drugs can’t build up to the levels needed to be effective.”
To Olive, that suggests, paradoxically, a longer-lived—but less toxic—drug may work better.
“For a pancreatic cancer drug to be effective, it needs to stick around long enough to seep past the stroma and accumulate in the tumor. But if it is going to persist for a long time in the blood, it can’t be as toxic to the rest of the body,” he says.
Pancreatic Ductal Adenocarcinoma
Despite some recent improvements in pancreatic cancer treatment, the five-year survival rate for individuals with this disease is only around 9%.
Testing a New Drug Combination
Olive’s latest research, which was led by Jaime Eberle-Singh, PhD, while she was a graduate student at Columbia, may have identified a good candidate. The drug, an experimental compound called PTC596 that had shown antitumor activity in mouse and human pancreatic cancer cells, seemed to have the right qualities: PTC596 has a durable half-life (most cancer drugs have a half-life of a few minutes to hours) and can evade a pump that many cancer cells use to expel drugs. “This means that any amount of drug that makes it past the barrier can target the malignant cells,” says Olive.
Based on those studies, Olive, Eberle-Singh, and their collaborators tested PTC596 in combination with gemcitabine (a first-line drug for pancreatic cancer) in genetically engineered mice with an aggressive form of pancreatic cancer that is generally resistant to chemotherapy.
The mice that were treated with the two-drug combination lived three times longer than those treated with only a single standard agent. “This result was exciting because it’s exceedingly rare for any treatment to extend survival in this gold-standard mouse model,” Olive says.
They also tested PTC596 in combination with gemcitabine and another drug commonly used to treat pancreatic cancer, nab-paclitaxel, using human pancreatic tumors grown in mice. This combination further enhanced efficacy, making the tumors shrink outright.
“Based on the drug’s safety profile and our own findings, there’s a good rationale for testing PTC596 in combination with standard therapy in patients with pancreatic cancer,” says Olive.
Olive’s team also discovered that PTC596 blocks the formation of microtubules—a network of proteins involved in cell division and transport of nutrients within the cell. He demonstrated that PTC596 may act synergistically with nab-paclitaxel, another microtubule-binding agent.
“Combining different microtubule inhibitors has the potential to play an important role in the future of oncology, as there are many agents that each impact microtubules in different ways that could produce synergy,” Olive says.
The Latest on: Pancreatic cancer
via Google News
The Latest on: Pancreatic cancer
- CytRx Highlights Use of Licensed Drug Aldoxorubicin in Treatment of Former Senate Majority Leader Harry Reid’s Pancreatic Canceron October 7, 2020 at 5:04 am
CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today ...
- NantKwest/ImmunityBio expand mid-stage pancreatic cancer studyon October 6, 2020 at 6:27 pm
NantKwest (NASDAQ:NK) and its collaborating partner ImmunityBio have announced to add a third cohort to ongoing Phase 2 immunotherapy trial for locally advanced or metastatic pancreatic cancer, and ...
- Yale cancer receives ACGT grant to advance strategies for treating pancreatic canceron October 6, 2020 at 6:40 am
Alliance for Cancer Gene Therapy (ACGT) gives $500,000 research grant to Sidi Chen, Ph.D., with Yale School of Medicine and Yale Cancer Center to advance strategies for treating pancreatic cancer ...
- Ruth Bader Ginsburg case highlights importance of early diagnosis for pancreatic canceron October 6, 2020 at 5:36 am
The recent death of Supreme Court Justice Ruth Bader Ginsburg is bringing more awareness to pancreatic cancer — the third leading cause of cancer deaths in the United States. Ginsburg's 11-year ...
- Hall of Famer, Cardinals legend Bob Gibson dies at 84 after battle with pancreatic canceron October 2, 2020 at 8:32 pm
Gibson becomes the second Cardinals Hall of Famer to die in the last month along with Lou Brock who died September 6.
- LI's pancreatic cancer walk goes virtual during pandemicon October 1, 2020 at 1:31 pm
When the 20th Long Island Walk for Pancreatic Cancer Research steps off this weekend, a very special survivor will be leading the way virtually. Joel Evans, 72, a Commack resident who is a five-year p ...
- Nonprofit Raises $1 Million for Pancreatic Cancer Researchon September 30, 2020 at 5:38 am
Sept. 20, nonprofit Purple Pansies received more than $1 million in donations to help end pancreatic cancer in their ...
- Competitive Scenario of Pancreatic Cancer Treatment Drugs Market Growth, Size, Demand, Forecast with Depth Assessment by Top Key Players 2025on September 29, 2020 at 11:58 pm
Global ""Pancreatic Cancer Treatment Drugs Market""(2020-2026) status and position of worldwide and key regions, ...
- Hackensack Meridian CDI Scientists Find One-Two Punch Working Against Stubborn Pancreatic Cancer in Preclinical Modelson September 29, 2020 at 6:50 am
PRNewswire/ -- A one-two punch of changing gene expression, then deploying immune checkpoint inhibitors, shows promise in battling one of the most treatment-resistant types of ...
- What coverage does Medicare provide for pancreatic cancer?on September 29, 2020 at 4:53 am
Medicare covers many treatments and services related to pancreatic cancer. Out-of-pocket costs may apply. Read on for more information.
via Bing News